title: Remission of hypercalciuria in patients with tuberculosis after treatment.
abstract: The hypercalciuria evolution and other bone metabolism parameters were evaluated in patients with tuberculosis after treatment. Twenty-two patients with tuberculosis and 54 normal subjects were studied; they consumed an average diet (calcium intake 1000 mg/day). Ten of these patients and nine normal subjects were also studied after a low calcium diet (400 mg/calcium/day) and after a load of oral calcium of 1000 mg (calcium absorption test). The study with an average diet was performed after 1 week (basal) and 3, 6, and 12 months after the antituberculosis treatment was started; the calcium absorption test was carried out 2 weeks, 3 and 12 months after the treatment was started. On an average diet, patients with tuberculosis presented, at baseline state, lower calcidiol levels than normal controls. Serum calcitriol levels at baseline were higher than at 6 and 12 months. Serum parathyroid hormone (PTH) levels in patients with tuberculosis were lower than in normal controls at baseline, but these levels were similar to controls at 3, 6, and 12 months after treatment. During the calcium absorption test and under basal conditions, patients with tuberculosis showed lower serum PTH and calcidiol levels in all the dietetic situations than in normal controls. However, serum calcitriol levels were higher than in controls after the restrictive diet. After 3 months of treatment, urinary calcium excretion was normal in patients with tuberculosis during the average and low diets, but higher than in control group after calcium load. After 12 months of treatment, all the biochemical parameters of the patients with tuberculosis were similar to the control group under all the dietetic situations. These data indicate that antituberculous treatment, although it may contribute to the production of some alteration in the calcium and vitamin D metabolism, basically favors the correction of disturbances associated with tuberculosis.
authors.affiliation: Biochemistry Department, Hospital "La Paz", Universidad Aut-onoma de Madrid, Paseo de la Castellana 261, 28046 Madrid, Spain.
authors.forename: M E
authors.initials: ME
authors.lastname: Martinez
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez
authors.forename: M J
authors.initials: MJ
authors.lastname: Sanchez-Cabezudo
authors.forename: J M
authors.initials: JM
authors.lastname: Peña
authors.forename: J J
authors.initials: JJ
authors.lastname: Vazquez
mesh_terms: D000328:Adult; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000652:urine*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D012074:Remission Induction; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000097:blood / Q000188:drug therapy / Q000652:urine*; D014807:Vitamin D / Q000097:blood
chemical_list: D010281:Parathyroid Hormone; D014807:Vitamin D; D002117:Calcitriol; D002118:Calcium; D007538:Isoniazid; D012293:Rifampin